

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent α -thalassemia, Using MRI Scans to Measure Iron Levels in the Body

NCT06421636

Status	RECRUITING
Phase	Phase 2
Sponsor	Regeneron Pharmaceuticals
Enrollment	95 participants

Key Eligibility Criteria

Inclusion (3)

- Clinical diagnosis of NTD as described in the protocol
- IOL, defined as LIC \geq 5 mg Fe/g DW as measured by R2* MRI at screening
- Serum ferritin \geq 300 ng/mL as described in the protocol

Exclusion (8)

- Hemoglobin \leq 8 g/dL at screening
- Any RBC transfusion within 12 weeks of visit 3
- For Part A only: Any Iron Chelation Therapy (ICT) use in approximately 12 weeks prior to screening as described in the protocol
- For Part B only: If on ICT, any change in ICT dose in approximately 12 weeks prior to screening as described in the protocol
- Any use of luspatercept or mitapivat in 6 months prior to screening as described in the protocol
- ... and 3 more (see full listing online)

Locations (26 total)

Weill Cornell Medicine, New York, New York, United States
K Eristavi National Center of Experimental and Clinical Surgery, Tbilisi, Georgia
Medinvest Institute of Hematology and Transfusiology Limited, Tbilisi, Georgia
... and 23 more locations